drugset / Trial / NCT04021862
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
RandomizedSequentialQuadruple-blindTreatment
Summary
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
Timeline
- Start
- 2019-10-16
- Primary completion
- 2020-06-30
- Completion
- 2020-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bermekimab | Monoclonal antibody | 400 mg | Subcutaneous |